Recent advances in immunotherapy for cervical cancer.

In combination therapy using an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor, tiragolumab and an anti-PD-L1 inhibitor, atezolizumab, the response rate was higher than with atezolizumab alone, although this did not reach statistical significance (SKYSCRAPER-04, NCT04300647 ) [ 34 ].

also in 111,027 other papers